Concord Biotech Ltd vs Corona Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Concord Biotech Ltd is ₹ 1184 as of 05 May 15:30 . The P/E Ratio of Concord Biotech Ltd changed from 51.7 on March 2024 to 0 on March 2022 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Corona Remedies Ltd changed from 0 on March 2023 to 0 on March 2022 . This represents a CAGR of 0.0% over 5 years The Market Cap of Concord Biotech Ltd changed from ₹ 15922 crore on March 2024 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 4 yearsThe Market Cap of Corona Remedies Ltd changed from ₹ 0 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of 0.0% over 5 years The revenue of Concord Biotech Ltd for the Dec '25 is ₹ 287.74 crore as compare to the Sep '25 revenue of ₹ 262.7 crore. This represent the growth of 9.53% The revenue of Corona Remedies Ltd for the Dec '25 is ₹ 344.68 crore as compare to the Sep '25 revenue of ₹ 363.57 crore. This represent the decline of -5.2% The ebitda of Concord Biotech Ltd for the Dec '25 is ₹ 104.98 crore as compare to the Sep '25 ebitda of ₹ 104.13 crore. This represent the growth of 0.82% The ebitda of Corona Remedies Ltd for the Dec '25 is ₹ 66.32 crore as compare to the Sep '25 ebitda of ₹ 80.91 crore. This represent the decline of -18.03% The net profit of Concord Biotech Ltd changed from ₹ 59.59 crore to ₹ 63.64 crore over 7 quarters. This represents a CAGR of 3.83% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 41.27 crore over 7 quarters. This represents a CAGR of 20.11% The Dividend Payout of Concord Biotech Ltd changed from 2.73 % on March 2022 to 24.54 % on March 2025 . This represents a CAGR of 73.15% over 4 yearsThe Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 years .

About Concord Biotech Ltd

Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies.
Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.
Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products.

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

FAQs for the comparison of Concord Biotech Ltd and Corona Remedies Ltd

Which company has a larger market capitalization, Concord Biotech Ltd or Corona Remedies Ltd?

Market cap of Concord Biotech Ltd is 12,393 Cr while Market cap of Corona Remedies Ltd is 10,718 Cr

What are the key factors driving the stock performance of Concord Biotech Ltd and Corona Remedies Ltd?

The stock performance of Concord Biotech Ltd and Corona Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Biotech Ltd and Corona Remedies Ltd?

As of May 5, 2026, the Concord Biotech Ltd stock price is INR ₹1184.65. On the other hand, Corona Remedies Ltd stock price is INR ₹1752.55.

How do dividend payouts of Concord Biotech Ltd and Corona Remedies Ltd compare?

To compare the dividend payouts of Concord Biotech Ltd and Corona Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.